Two RCTs or Nothing: What FTC Orders Leave Behind

what exactly did the ftc find across pom wonderful's advertising?

On January 16, 2013, the FTC upheld an administrative law judge's finding that advertisers behind POM Wonderful 100% Pomegranate Juice and POMx marketed the products as able to treat, prevent, or reduce the risk of heart disease, prostate cancer, and erectile dysfunction. Per the FTC's January 2013 release, the Commission found 36 individual advertisements deceptive. POM argued it was simply reporting promising research. The Commission didn't accept that framing: the Final Order bars claiming a food, drug, or supplement is "effective in the diagnosis, cure, mitigation, treatment, or prevention of any disease" without adequate proof.

We counted 36 separate ads in that finding — not one flagship claim.

The named respondents included POM Wonderful, LLC and its owners, Stewart and Lynda Resnick, along with several corporate affiliates. The order reached the individuals who controlled the marketing, not just the corporate entity that ran it — a distinction worth checking if you're vetting who actually stands behind a heart-health offer today.

why does the final order require two randomized human clinical trials?

The FTC set that bar because claims to treat, prevent, or reduce the risk of a specific, serious disease sit at the top of the agency's evidence hierarchy. Its December 2022 guidance states that "substantiation of health-related benefits will need to be in the form of randomized, controlled human clinical testing" — RCTs, in the shorthand advertisers use — because a single study inviting alternative explanations wasn't enough for the Commission to trust it for a claim about heart disease or cancer. Two independent trials were meant to rule out the chance that one result was a fluke of that particular sample.

One trial can look like an accident; two, far less easily.

Heart disease sits in a special category for regulators generally, worth noting even outside this case: FDA's own definition of "disease" uses cardiovascular disease as its lead example, and the harm from a wrong claim there is judged too severe for anything short of trial-grade evidence.

what happened to the first amendment defense in that case?

The First Amendment argument won a narrowing of the remedy, not a dismissal of liability. On January 30, 2015, the D.C. Circuit agreed that requiring two randomized, well-controlled human clinical trials for every future disease claim was more speech restriction than the case justified, and cut the requirement to one trial. The court left the underlying deception finding untouched: the 36 ads were still deceptive, and the respondents were still liable for running them. The Supreme Court denied certiorari on May 2, 2016, and the FTC issued its modified order on June 14, 2016.

One RCT survived judicial review; two did not.

For advertisers, the floor moved but it didn't disappear. One well-designed randomized human trial still beats the industry's default of citing somebody else's in vitro study or a founder's personal experience — and it still costs real money and real time to produce.

what did the ultimate heart formula case charge?

The FTC's complaint against Health Research Laboratories, LLC, Whole Body Supplements, and owner Kramer Duhon charged that three products — The Ultimate Heart Formula (UHF), BG18, and Black Garlic Botanicals — were marketed on unsubstantiated claims that they "prevent or treat cardiovascular and other diseases." The complaint didn't challenge the ingredients themselves; it challenged the absence of the human trial that FTC guidance treats as the baseline for a disease claim of this kind.

No trial meant no substantiation, and no substantiation meant no lawful claim.

The proposed order arrived in March 2022 and was finalized that June — a four-month gap that mattered far less than what came before it. That earlier history, not the products themselves, is what turned this into a company-ending case, and it's where the next question picks up.

why did a prior settlement make the second health research labs case worse?

The 2022 case followed an earlier settlement with the FTC and the State of Maine, and per FTC's March 2022 release, that prior history is what turned a routine false-claims order into an industry-wide ban. Regulators read a second offense after a first settlement as evidence the company understood the rules and broke them anyway — recidivism, not ignorance. Under the March 2022 agreement, finalized that June, the order didn't just require Kramer Duhon and his companies to stop the specific heart-disease claims: it barred them from advertising or selling dietary supplements in any form, a remedy well past what a typical first-time violator faces, and the clearest signal in this record that a repeat offense gets priced differently than a first one, whatever the underlying science says.

History counted against them, twice.

Any operator carrying a signed FTC order in their file is one repeat claim away from the same outcome — not a fresh warning letter, but the industry-exit remedy this case shows in full. That's the risk worth pricing into any offer tied to a name with history.

what does an industry ban actually prohibit the operators from doing?

An industry ban like Duhon's prohibits advertising or selling dietary supplements at all, not just correcting the disease claims that triggered the case. The order bars him and his companies from the underlying business entirely, a step beyond a standard cease-and-desist that only forbids specific representations. It carries the disease-claim prohibitions any FTC health order does on top of that: no claiming a product treats, cures, or reduces the risk of disease without competent and reliable scientific evidence.

A ban like this ends a career in supplements, not just a single campaign.

• Advertising or selling any dietary supplement, not only the three products named in the complaint
• Making any disease-treatment or disease-prevention claim without competent and reliable scientific evidence behind it
• Misrepresenting the existence, contents, or results of any test, study, or clinical trial used to support a claim

does animal or in vitro evidence ever carry a health benefit claim?

Animal and in vitro studies alone cannot carry a disease-treatment claim under FTC's standard; they can support a research narrative, but not an advertisement aimed at consumers. FTC's Health Products Compliance Guidance treats human trial confirmation as what closes the gap between a laboratory result and a marketing claim, not a study run on cells or on animals. A cell-culture study showing an ingredient inhibits inflammation in a petri dish says nothing about whether a capsule lowers a person's risk of heart disease.

A petri dish is not a patient.

Epidemiological studies fare no better standing alone — they show correlation, not proof that a product caused the outcome. We checked whether animal or in vitro evidence alone has ever cleared a heart-disease claim in FTC's public settlement record; it hasn't.

how should a media buyer read order remedies before picking a heart offer?

Read the remedy before you read the claim on the landing page. Many media buyers treat the boldface FDA disclaimer as insurance against exactly the outcome POM and HRL show — it isn't. FTC guidance treats a disclaimer as no defense when it directly contradicts the claim next to it, describing a comparable disclaimer as "directly contradictory and ineffective to negate the acne treatment claim" it sat beside. The same reasoning reaches a "not evaluated by the FDA" box glued under a cardiovascular-disease promise: the box doesn't cancel the sentence above it.

Check the name on the order, not just the name on the bottle.

We could not verify current US cardiovascular disease prevalence or the age profile of a typical heart-health buyer from a live primary source; cdc.gov returned an access error to our own check during research for this page. A working pull from CDC or NIH would settle the exact share of your audience already carrying a diagnosis, which matters directly for how close a "heart health" angle can legally sit to disease language.

Before you run a heart-health angle, decide which ceiling you're building toward. The ordinary one, from POM, lets a single well-designed human trial keep a specific claim alive. The escalated one, from HRL, costs the right to sell supplements at all after a second offense — and per FTC's April 2023 penalty-offense release, roughly 670 companies now sit on notice that the same missing trial can mean a civil penalty rather than a second warning.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Offers Targeting GLP-1 Users: The Side-Effect Economy, Best Nutra Affiliate Networks: Ranked by Offer Depth, Probiotic Weight Loss Offers: The Gut-Slim Ad Angle, Best GEOs for Nutra Offers in 2026: A Data Tier List, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.